P3 Health Partners (NASDAQ:PIII – Get Free Report) and KORU Medical Systems (NASDAQ:KRMD – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.
Profitability
This table compares P3 Health Partners and KORU Medical Systems’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| P3 Health Partners | -9.07% | -302.33% | -16.72% |
| KORU Medical Systems | -9.49% | -22.43% | -13.86% |
Institutional & Insider Ownership
7.8% of P3 Health Partners shares are owned by institutional investors. Comparatively, 58.6% of KORU Medical Systems shares are owned by institutional investors. 17.8% of P3 Health Partners shares are owned by company insiders. Comparatively, 20.6% of KORU Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| P3 Health Partners | 1 | 1 | 1 | 0 | 2.00 |
| KORU Medical Systems | 1 | 1 | 3 | 1 | 2.67 |
P3 Health Partners presently has a consensus target price of $12.50, indicating a potential upside of 203.40%. KORU Medical Systems has a consensus target price of $5.13, indicating a potential downside of 11.64%. Given P3 Health Partners’ higher probable upside, equities research analysts clearly believe P3 Health Partners is more favorable than KORU Medical Systems.
Volatility and Risk
P3 Health Partners has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, KORU Medical Systems has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500.
Earnings and Valuation
This table compares P3 Health Partners and KORU Medical Systems”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| P3 Health Partners | $1.50 billion | 0.02 | -$135.85 million | ($40.18) | -0.10 |
| KORU Medical Systems | $33.65 million | 7.98 | -$6.07 million | ($0.08) | -72.50 |
KORU Medical Systems has lower revenue, but higher earnings than P3 Health Partners. KORU Medical Systems is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.
Summary
KORU Medical Systems beats P3 Health Partners on 10 of the 15 factors compared between the two stocks.
About P3 Health Partners
P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.
About KORU Medical Systems
KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.
Receive News & Ratings for P3 Health Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for P3 Health Partners and related companies with MarketBeat.com's FREE daily email newsletter.
